In today’s episode, Ian King speaks with Dan Ives – managing director of the brokerage and advisory firm Wedbush Securities – to discuss Microsoft’s revenues and AI.
Ian Johnston, global pharmaceutical correspondent at the Financial Times, discusses sales of popular weight loss drug ‘Wegvoy’, made by Novo Nordisk – as they say their sales almost quadrupled last year.
And, Ian discusses GSK’s operating profit of £8.8bn for 2023 with strong selling medicines including its HIV and shingles medication.
Related posts:
Fracking firm makes its case as PM eyes North Sea gas solution to price crisis
London-listed adtech firm Tremor in talks to buy £165m rival from Singtel
‘Fragile’ hospitality industry ‘cannot withstand economic shock’ of rail strikes
‘Hospitality in freefall’: Restaurants and food outlets going bust up by almost 50%
Aggreko lines up £110m takeover of London-listed power supplier Crestchic
US inflation falls to 6% making Fed’s expected interest rate rise even less likely
Health of European banks in focus as stocks plunge again over Credit Suisse and rate rise worries
Italy introduces surprise windfall tax on banks’ interest rate profits
Worst of inflation behind us but price rises to come for vegetables and salad items, Morrisons boss says
Scandal-hit care group Hesley sold to new private investor
Top Telegraph staff in line for windfalls as sale looms
Abu Dhabi state-backed fund moves to take control of Daily Telegraph
